文献速递乳腺癌

中国乳腺癌新辅助治疗现状横断面研究

[Current trend of breast cancer neoadjuvant treatment in China: a cross-sectional study].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该研究于2018年7至9月对110家年乳腺癌手术量超200例的医院进行问卷调查,了解新辅助治疗的肿瘤分期、分子分型、方案、疗效评估及手术操作现状。可手术乳腺癌中新辅助治疗占比仍偏低,降阶梯手术观念未广泛推广,疗效评估手段有待规范。

要点

  • 新辅助患者中HER-2阳性占41.4%,三阴性占34.3%,ER阳性HER-2阴性占24.4%。
  • 87.3%的医院新辅助后保乳率低于20%,降阶梯手术观念未广泛推广。

核心结论

  • 乳腺癌新辅助治疗已在中国大部分医院开展,但可手术乳腺癌中新辅助治疗占比仍偏低。
  • 通过新辅助治疗实现手术降阶梯的观念未得到广泛推广。
  • 新辅助治疗疗效评价手段有待进一步规范。

研究设计与样本

  • 横断面问卷调查,于2018年7月至9月向110家年乳腺癌手术量超过200例的医院发放问卷。
  • 调查内容包括新辅助治疗患者的肿瘤分期和分子分型、治疗方案、疗效评估及相关手术操作。

主要发现

  • Ⅱ期患者占比低于30%的医院有81家,Ⅲ期患者占比超过50%的医院有84家。
  • 影响新辅助治疗开展的主要原因为患者对延迟手术存在顾虑及新辅助治疗后保乳意愿不强。
  • 87.3%的医院新辅助治疗后患者保乳率低于20%。

关键数值与推荐

  • 53.6%的医院最常用蒽环类续贯紫杉类方案,42.7%的医院首选蒽环类联合紫杉类方案。
  • 80.9%的医院对HER-2阳性患者推荐含靶向治疗的新辅助方案。
  • 42.7%的医院在超过50%患者中使用MRI评估疗效,37.3%的医院MRI使用率低于20%。
  • 将反复划线、纹身及金属夹植入作为原发灶及淋巴结首选标记方法的医院分别占60.0%、29.1%和10.9%。

临床怎么用

  • 应关注可手术乳腺癌中新辅助治疗占比偏低的问题,结合患者顾虑与保乳意愿进行个体化沟通。
  • HER-2阳性患者新辅助治疗应优先考虑含靶向治疗方案。
  • 需规范新辅助治疗疗效评估手段,合理使用MRI并统一原发灶及淋巴结标记方法。

局限性

  • 研究为问卷调查,未报告应答率及数据完整性等细节。
  • 调查对象为年手术量超过200例的医院,结果可能不能代表全部医疗机构。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the current trend of breast cancer neoadjuvant therapy and provide reference for the improvement of breast cancer clinical guideline in the future. Methods: Questionnaires of cross-sectional survey were sent to 110 hospitals (breast cancer surgery quantity surpassing 200) between July 2018 and September 2018. The stages and subtypes, therapeutic regimen, treatment assession, operation choice and preforming of patients underwent neoadjuvant therapy were recorded. Results: Neoadjuvant treatment has been performed in all of the 110 hospitals. The total number of breast patients underwent neoadjuvant therapy was about 14 550 (17.0% in surgical patients) in 2017. For all of the neoadjuvant patients, the proportion of stageⅡ patients was less than 30% in 81 hospitals, and the proportion of stage Ⅲ was more than 50% in 84 hospitals. The numbers of estrogen receptor (ER) (+ )/human epidermal growth factor receptor-2 (HER-2) (-), ER (-)/HER-2 (+ ) and triple negative subtype breast cancer patients were 3 550 (24.4%), 6 024 (41.4%) and 4 991 (34.3%), respectively. Patient's scruples of relatively delayed operation and weak will of breast conservation after neoadjuvant therapy were the majority reasons for neoadjuvant therapy restriction. Anthracycline followed by taxane was the most usual neoadjuvant therapeutic regimens in 53.6% hospitals, and anthracycline plus taxane was the first choice in 42.7% hospitals. Chemotherapy with targeting therapy was recommended to HER-2 positive neoadjuvant patients in 80.9% hospitals. To assess treatment outcome of neoadjuvant treatment, 42.7% hospitals used MRI in more than 50% patients while the usage rate of MRI was less than 20% in 37.3% hospitals. The proportions of hospital using repeat-marking, tattoo and metal clip as the first method to identify the primary tumor region and lymph nodes were 60.0%, 29.1% and 10.9%, respectively. Breast-conservation rate after neoadjuvant therapy was less than 20% in 87.3% hospitals. Conclusions: Neoadjuvant therapy for breast cancer is widely performed in most hospitals in China, while the proportion of neoadjuvant treatment in patients with operable breast cancer is still low. Meanwhile, the idea of achieving de-escalation operation through neoadjuvant treatment is not promoted and the therapeutic evaluation method of neoadjuvant treatment needs further studies to improve. 目的: 了解中国乳腺癌新辅助治疗的现状,为未来乳腺癌的诊疗规范改进提供参考依据。 方法: 2018年7月到2018年9月对110家乳腺癌年手术量超过200例的医院进行问卷调查,内容包括新辅助治疗患者的肿瘤分期和分子分型、治疗方案、疗效评估及相关手术操作的开展等。 结果: 110家医院均已开展乳腺癌的新辅助治疗,2017年共行新辅助治疗14 550例,占手术治疗乳腺癌患者的17.0%。行新辅助治疗的乳腺癌患者中Ⅱ期患者占比<30%的医院有81家;Ⅲ期患者占比>50%的医院有84家。新辅助治疗患者中,雌激素受体(ER)阳性人表皮生长因子受体2(HER-2)阴性3 550例(24.4%),HER-2阳性6 024例(41.4%),三阴性4 991例(34.3%)。影响新辅助治疗开展的主要原因是"患者对延迟手术存在顾虑"和"患者通过新辅助治疗后的保乳意愿不强"。53.6%的医院最常用的新辅助治疗方案为蒽环类药物续贯紫杉类药物,42.7%的医院首选蒽环类药物联合紫杉类药物。对于HER-2阳性患者,80.9%的医院会推荐含靶向治疗的新辅助治疗方案。37.3%的医院将MRI用于新辅助治疗疗效评估的使用率在20%以下,而42.7%的医院在50%以上。将反复划线、纹身及金属夹植入分别作为新辅助治疗患者肿瘤原发灶及淋巴结首选标记方法的医院分别占60.0%、29.1%和10.9%。87.3%的医院新辅助治疗后患者保乳率低于20%。 结论: 乳腺癌的新辅助治疗已在中国大部分医院开展,然而新辅助治疗在可手术乳腺癌中的占比仍然偏低。乳腺癌通过新辅助治疗以完成手术降阶梯的观念未得到广泛推广,新辅助治疗疗效评价手段有待进一步规范。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang J, Xiu BQ, Guo R, et al. [Current trend of breast cancer neoadjuvant treatment in China: a cross-sectional study]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 33256304. doi:10.3760/cma.j.cn112152-20190924-00623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。